

RECENT SCIENTIFIC LITERATURE ON THE BENEFITS AND MECHANISMS OF ACTION OF N-ACETYL-CYSTEINE (NAC) IN THE TREATMENT OF COVID-19 AND DETOXIFICATION OF SPIKE PROTEIN

2022

Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV. Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation. *Antioxidants (Basel)*. 2021;11(1):50. Published 2021 Dec 27. doi:10.3390/antiox11010050
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773164/>

Di Marco F, Foti G, Corsico AG. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19? *Eur Rev Med Pharmacol Sci*. 2022 Jan;26(2):715-721. doi: 10.26355/eurrev_202201_27898. PMID: 35113447.
<https://www.europeanreview.org/wp/wp-content/uploads/715-721.pdf>

Perla-Kaján J, Jakubowski H. COVID-19 and One-Carbon Metabolism. *Int J Mol Sci*. 2022;23(8):4181. Published 2022 Apr 10. doi:10.3390/ijms23084181
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026976/>

Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikhanov ZG. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. *J Infect*. 2022;84(1):94-118. doi:10.1016/j.jinf.2021.07.003
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271031/>

Suhail S, Zajac J, Fossum C, et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. *Protein J*. 2020;39(6):644-656. doi:10.1007/s10930-020-09935-8
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587547/>

Chen B, Raja K, Pierre-Louis F, et al. Intravenous N-Acetylcysteine in Management of COVID-19: A Case Series [published online ahead of print, 2022 Mar 24]. *J Pharm Pract*. 2022;8971900221080283. doi:10.1177/08971900221080283
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958286/>

Izquierdo JL, Soriano JB, González Y, et al. Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. *Sci Prog*. 2022;105(1):368504221074574. doi:10.1177/00368504221074574
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795755/>

Coelho Dos Reis JGA, Ferreira GM, Lourenço AA, et al. Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19. *Biomed Pharmacother*. 2022;148:112753. doi:10.1016/j.biopha.2022.112753
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872962/>

Goc A, Niedzwiecki A, Ivanov V, Ivanova S, Rath M. Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants. *Eur J Microbiol Immunol (Bp)*. 2022;11(4):87-94. Published 2022 Jan 21. doi:10.1556/1886.2021.00022
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830412/>

Murae M, Shimizu Y, Yamamoto Y, et al. The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione [published online ahead of print, 2022 Jan 29]. *Biochem Biophys Res Commun*. 2022;597:30-36. doi:10.1016/j.bbrc.2022.01.106
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800159/>

Chen G, Lu H. Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? *Drug Discov Ther*. 2022 May 6. doi: 10.5582/ddt.2022.01032. Epub ahead of print. PMID: 35527020.
<https://pubmed.ncbi.nlm.nih.gov/35527020/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864717/>

Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M and Gut P (2022) A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. *Front. Aging 3:852569*. doi: 10.3389/fragi.2022.852569

<https://www.frontiersin.org/articles/10.3389/fragi.2022.852569/full>

Lapenna D. Regarding: Hypoalbuminemia in COVID-19. *J Intern Med.* 2022;291(3):388-389. doi:10.1111/joim.13403
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661995/>

El Shehaby, D.M., Mohammed, M., Ebrahim, N.E. et al. The emerging therapeutic role of some pharmacological antidotes in management of COVID-19. *Egypt J Bronchol* 16, 5 (2022). <https://doi.org/10.1186/s43168-021-00105-7>

Outcomes in COVID-19 N-acetylcysteine studies
<https://c19early.com/nameta.html>

<https://www.marketwatch.com/press-release/acetylcysteine-market-2022-scope-of-the-report-challenges-and-trends-growing-market-with-covid-19-impact-key-regions-and-key-players-analysis-by-2028-2022-03-08>

Vestibular Paroxysmia Successfully Treated with N-acetylcysteine: A Case Report (P13-12.002)
Courtney Iser, Karissa Arca, David Dodick, Jamie Bogle
Neurology May 2022, 98 (18 Supplement) 1662; https://n.neurology.org/content/98/18_Supplement/1662

2021

Grishin AM, Dolgova NV, Harms S, et al. Spike protein disulfide disruption as a potential treatment for SARS-CoV-2. *bioRxiv* 2021 Jan 4. (Preprint)
(<https://doi.org/10.1101/2021.01.02.425099>)
<https://www.biorxiv.org/content/10.1101/2021.01.02.425099v1.full.pdf>

Manček-Keber M, Hafner-Bratkovič I, Lainšček D, et al. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. *FASEB J.* 2021;35(6):e21651. doi:10.1096/fj.202100560R
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206760/>

Santos AF, Póvoa P, Paixão P, Mendonça A, Taborda-Barata L. Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19. *Front Chem.* 2021;9:685196. Published 2021 Sep 10. doi:10.3389/fchem.2021.685196
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461303/>

Martin BR, Richardson J. An Exploratory Review of Potential Adjunct Therapies for the Treatment of Coronavirus Infections. *J Chiropr Med.* 2021;20(4):199-217. doi:10.1016/j.jcm.2021.12.005
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664662/>

Menicagli R, Limodio M, Limodio M, Casotti MT, Menicagli L. Pulmonary Covid Fibrosis a New Pharmaceutic Approach. *Int J Prev Med.* 2021;12:35. Published 2021 Mar 29. doi:10.4103/ijpvm.IJPVM_462_20
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218809/>

Chavarría AP, Vázquez RRV, Cherit JGD, et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. *Comput Struct Biotechnol J.* 2021;19:1379-1390. doi:10.1016/j.csbj.2021.02.009
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910139/>

Darenskaya M, Kolesnikova L, Kolesnikov S. The Association of Respiratory Viruses with Oxidative Stress and Antioxidants. Implications for the COVID-19 Pandemic. *Curr Pharm Des.* 2021;27(13):1618-1627. doi: 10.2174/1381612827666210222113351. PMID: 33618639.
<https://pubmed.ncbi.nlm.nih.gov/33618639/>

Ribeiro TB, Mazotti TA, Silva NAO, Stein AT, Diaz-Quijano FA, Melo DO. Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. *Rev Bras Epidemiol.* 2021 Jan 6;23:e200104. Portuguese, English. doi: 10.1590/1980-549720200104. Erratum in: *Rev Bras Epidemiol.* 2021 May 24;24:e200104ERRATUM. PMID: 33439937.
<https://doi.org/10.1590/1980-549720200104>

Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. *Pharmacol Rep.* 2021;73(6):1650-1659. doi:10.1007/s43440-021-00296-2
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191712/>

McCarty MF, Iloki Assanga SB, Lewis Luján L, O'Keefe JH, DiNicolantonio JJ. Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. *Nutrients*. 2020;13(1):47. Published 2020 Dec 25. doi:10.3390/nu13010047 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823562/>

Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, Kazemijahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021;22(1):271. Published 2021 Apr 12. doi:10.1186/s13063-021-05242-4 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040363/>

Dominari A, Hathaway Iii D, Kapasi A, et al. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. *World J Virol*. 2021;10(2):34-52. doi:10.5501/wjv.v10.i2.34 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995409/>

Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, Oikonomou I, Mouzaki A, Marangos M. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. *Infect Dis (Lond)*. 2021 Nov;53(11):847-854. doi: 10.1080/23744235.2021.1945675. Epub 2021 Jun 29. PMID: 34182881. <https://pubmed.ncbi.nlm.nih.gov/34182881/>

Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H₂S and sulfane sulfur species. *Pharmacol Ther*. 2021 Dec;228:107916. doi: 10.1016/j.pharmthera.2021.107916. Epub 2021 Jun 23. PMID: 34171332. <https://doi.org/10.1016/j.pharmthera.2021.107916>

Cárdenas-Rodríguez N, Bandala C, Vanoye-Carlo A, Ignacio-Mejía I, Gómez-Manzo S, Hernández-Cruz EY, Pedraza-Chaverri J, Carmona-Aparicio L, Hernández-Ochoa B. Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. *Antioxidants (Basel)*. 2021 Jun 17;10(6):971. doi: 10.3390/antiox10060971. PMID: 34204362; PMCID: PMC8235474. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235474/>

Zhou N, Yang X, Huang A, Chen Z. The Potential Mechanism of N-acetylcysteine in Treating COVID-19. *Curr Pharm Biotechnol*. 2021;22(12):1584-1590. doi: 10.2174/1389201021999201228212043. PMID: 33371832. <https://pubmed.ncbi.nlm.nih.gov/33371832/>

de Alencar JCG, Moreira CL, Müller AD, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*. 2021;72(11):e736-e741. doi:10.1093/cid/ciaa1443 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543361/>

Wong KK, Lee SWH, Kua KP. N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence. *J Inflamm Res*. 2021;14:2993-3013. Published 2021 Jul 6. doi:10.2147/JIR.S306849 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274825/>

Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. *Eur Rev Med Pharmacol Sci*. 2021 Mar;25(6):2802-2807. doi: 10.26355/eurrev_202103_25442. PMID: 33829465. <https://www.europeanreview.org/article/25442>

Lana JFSD, Lana AVSD, Rodrigues QS, Santos GS, Navani R, Navani A, da Fonseca LF, Azzini GOM, Setti T, Mosaner T, Simplicio CL, Setti TM. Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset. *Adv Redox Res*. 2021 Dec;3:100015. doi: 10.1016/j.arres.2021.100015. Epub 2021 Aug 8. PMID: 35425932; PMCID: PMC8349474. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349474/>

Qiao Q, Liu X, Yang T, et al. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. *Acta Pharm Sin B*. 2021;11(10):3060-3091. doi:10.1016/j.apsb.2021.04.023 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102084/>

Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. *Antioxid Redox Signal*. 2021 Nov 10;35(14):1207-1225. doi: 10.1089/ars.2020.8247. Epub 2021 Mar 25. PMID: 33607929. <https://pubmed.ncbi.nlm.nih.gov/33607929/>

Cazzola M, Rogliani P, Salvi SS, Ora J, Matera MG. Use of Thiols in the Treatment of COVID-19: Current Evidence. *Lung*. 2021;199(4):335-343. doi:10.1007/s00408-021-00465-3 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390541/>

Grieb P, Swiatkiewicz M, Prus K, Rejdak K. Hypoxia may be a determinative factor in COVID-19 progression. *Curr Res Pharmacol Drug Discov.* 2021;2:100030. doi:10.1016/j.crphar.2021.100030
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106824/>

Hussain M, Khurram Syed S, Fatima M, et al. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. *J Inflamm Res.* 2021;14:7225-7242. Published 2021 Dec 21. doi:10.2147/JIR.S334043
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710428/>

Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF- κ B, inflammation and cytokine storm in COVID-19. *Int Immunopharmacol.* 2021;101(Pt B):108255. doi:10.1016/j.intimp.2021.108255
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516728/>

Akhter J, Quémès G, Pillai K, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. *Viruses.* 2021;13(3):425. Published 2021 Mar 6. doi:10.3390/v13030425
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999995/>

Rafiee B, Bagher Tabei SM. The effect of N-acetyl cysteine consumption on men with abnormal sperm parameters due to positive history of COVID-19 in the last three months. *Arch Ital Urol Androl.* 2021 Dec 21;93(4):465-467. doi: 10.4081/aiua.2021.4.465. PMID: 34933532.
<https://www.pagepressjournals.org/index.php/aiua/article/view/aiua.2021.4.465>

DE Flora S, Balansky R, LA Maestra S. Antioxidants and COVID-19. *J Prev Med Hyg.* 2021;62(1 Suppl 3):E34-E45. Published 2021 Jun 5. doi:10.15167/2421-4248/jpmh2021.62.1S3.1895
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452284/>

Kontoghiorghes GJ, Fetta S, Kontoghiorghes CN. The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic. *Front Biosci (Landmark Ed).* 2021 Dec 30;26(12):1723-1736. doi: 10.52586/5064. PMID: 34994185.
<https://www.imrpess.com/journal/FBL/26/12/10.52586/5064>

Fratta Pasini AM, Stranieri C, Cominacini L, Mozzini C. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. *Antioxidants (Basel).* 2021;10(2):272. Published 2021 Feb 10. doi:10.3390/antiox10020272
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916604/>

Bernard Demot, Kristin Ivan Mark Hizon, 538. The Role of N-acetylcysteine on Post Covid-19 Pulmonary Fibrosis, *Open Forum Infectious Diseases*, Volume 8, Issue Supplement_1, November 2021, Pages S370–S371, <https://doi.org/10.1093/ofid/ofab466.737>

Faverio P, Rebora P, Rossi E, et al. Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. *ERJ Open Res.* 2021;8(1):00542-2021. Published 2021 Feb 7. doi:10.1183/23120541.00542-2021
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646003/>

Wang R, Chan JF, Wang S, et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. *Chem Sci.* 2021;13(8):2238-2248. Published 2021 Dec 3. doi:10.1039/d1sc04515f

Raghu G, Berk M, Campochiaro PA, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. *Curr Neuropharmacol.* 2021;19(8):1202-1224. doi:10.2174/1570159X19666201230144109
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719286/>

Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. *Antioxid Redox Signal.* 2021 Nov 10;35(14):1207-1225. doi: 10.1089/ars.2020.8247. Epub 2021 Mar 25. PMID: 33607929.
<https://www.liebertpub.com/doi/10.1089/ars.2020.8247>

2020

- Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. *Med Hypotheses*. 2020;143:109862. doi:10.1016/j.mehy.2020.109862
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261085/>
- Shi Z, Puyo CA. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Ther Clin Risk Manag*. 2020;16:1047-1055. Published 2020 Nov 2. doi:10.2147/TCRM.S273700
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/>
- De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *FASEB J*. 2020;34(10):13185-13193. doi:10.1096/fj.202001807
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436914/>
- Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. *In Vivo*. 2020;34(3 Suppl):1567-1588. doi:10.21873/invivo.11946
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378025/>
- Jorge-Aarón RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. *Future Microbiol*. 2020;15:959-962. doi:10.2217/fmb-2020-0074
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359418/>
- Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? *Cleve Clin J Med*. 2020 Jun 8. doi: 10.3949/ccjm.87a.ccc046. Epub ahead of print. PMID: 32513807.
<https://www.ccjm.org/content/early/2020/06/08/ccjm.87a.ccc046.long>
- Luo P, Liu Y, Liu D, Li J. Perspectives for the Use of N-acetylcysteine as a Candidate Drug to Treat COVID-19. *Mini Rev Med Chem*. 2021;21(3):268-272. doi: 10.2174/1389557520666201027160833. PMID: 33109047.
<https://pubmed.ncbi.nlm.nih.gov/33109047/>
- Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin Immunol*. 2020;219:108544. doi:10.1016/j.clim.2020.108544
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374140/>
- Wu J. Tackle the free radicals damage in COVID-19. *Nitric Oxide*. 2020;102:39-41. doi:10.1016/j.niox.2020.06.002
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837363/>
- Ferreira AO, Polonini HC, Dijkers ECF. Postulated Adjuvant Therapeutic Strategies for COVID-19. *J Pers Med*. 2020;10(3):80. Published 2020 Aug 5. doi:10.3390/jpm10030080
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565841/>
- Silvagno F, Vernone A, Pescarmona GP. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. *Antioxidants (Basel)*. 2020;9(7):624. Published 2020 Jul 16. doi:10.3390/antiox9070624
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402141/>
- Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. *Eur J Pharmacol*. 2020;885:173494. doi:10.1016/j.ejphar.2020.173494
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440159/>
- Liu Y, Wang M, Luo G, et al. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report. *Medicine (Baltimore)*. 2020;99(42):e22577. doi:10.1097/MD.00000000000022577
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571913/>
- Atefi N, Behrangi E, Mozafarpour S, Seirafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. *J Res Med Sci*. 2020;25:109. Published 2020 Nov 26. doi:10.4103/jrms.JRMS_777_20
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019127/>
- Daid SS, Toribio AD, Lakshmanan S, Satta A, Epstein A. Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19. *Cureus*. 2020;12(9):e10447. Published 2020 Sep 14. doi:10.7759/cureus.10447
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557520/>

DiNicolantonio JJ, Barroso-Aranda J. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. *Med Hypotheses*. 2020;143:110051. doi:10.1016/j.mehy.2020.110051 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330590/>

Guglielmetti G, Quaglia M, Sainaghi PP, et al. "War to the knife" against thromboinflammation to protect endothelial function of COVID-19 patients. *Crit Care*. 2020;24(1):365. Published 2020 Jun 19. doi:10.1186/s13054-020-03060-9 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303575/>

Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. *Pharmacotherapy*. 2020;40(11):1166-1171. doi:10.1002/phar.2464 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537093/>

Hamidi Alamdari D, Bagheri Moghaddam A, Amini S, Hamidi Alamdari A, Damsaz M, Yarahmadi A. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol. *Arch Bone Jt Surg*. 2020;8(Suppl1):291-294. doi:10.22038/abjs.2020.47745.2349 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296601/>

Nasi A, McArdle S, Gaudernack G, et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. *Toxicol Rep*. 2020;7:768-771. Published 2020 Jun 18. doi:10.1016/j.toxrep.2020.06.003 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301821/>

Polonikov A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. *ACS Infect Dis*. 2020;6(7):1558-1562. doi:10.1021/acsinfecdis.0c00288 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263077/>